Sonnet BioTherapeutics Holdings, Inc. (SONN) Tops Q3 EPS by 16c

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) reported Q3 EPS of ($0.13), $0.16 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $36.85 million.

For earnings history and earnings-related data on Sonnet BioTherapeutics Holdings, Inc. (SONN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal